Search

Your search keyword '"Xue XY"' showing total 259 results

Search Constraints

Start Over You searched for: Author "Xue XY" Remove constraint Author: "Xue XY"
259 results on '"Xue XY"'

Search Results

1. Development and Validation of Hub Genes for Adrenal Aldosterone-Producing Adenoma by Integrated Bioinformatics Analysis

2. Angiogenesis-Related Molecular Subtypes and a Novel Prognostic Signature in Clear Cell Renal Cell Carcinoma Patients

3. Mesenchymal Stem Cell-Derived Exosomes Induced by IL-1β Attenuate Urethral Stricture Through Let-7c/PAK1/NF-κB-Regulated Macrophage M2 Polarization

4. Predictors of Prolonged Laparoscopic Radical Prostatectomy and the Creation of a Scoring System for the Duration

5. Predictors Of Postoperative Lower Urinary Tract Symptoms Improvements In Patient With Small-Volume Prostate And Bladder Outlet Obstruction

6. Identification of key genes and pathways in seminoma by bioinformatics analysis

7. Fasudil inhibits actin polymerization and collagen synthesis and induces apoptosis in human urethral scar fibroblasts via the Rho/ROCK pathway

8. Risk factors for infectious complications following transrectal ultrasound-guided prostate biopsy

9. Upregulation of Arp2 expression is associated with the prognosis and prediction of lymph node metastasis in bladder urothelial carcinoma

10. Sex-related differences in clinicopathological features and survival of patients with primary urethral carcinoma: a population-based study

12. Visual Attention Based Motion Object Detection and Trajectory Tracking

15. Raman Active Phonons in RCoO3 (R=La, Ce, Pr, Nd, Sm, Eu, Gd, and Dy) Perovskites

16. Visual Attention Based Motion Object Detection and Trajectory Tracking

17. Liquid-liquid phase separation-related genes associated with prognosis, tumor microenvironment characteristics, and tumor cell features in bladder cancer.

18. Machine learning-based autophagy-related prognostic signature for personalized risk stratification and therapeutic approaches in bladder cancer.

19. A Novel Classification System of Renal Hilar Tumors for Surgical Guidance: Technique, Outcome, and Safety.

20. Idiopathic aplastic anemia with concurrent complications of colonic perforation and mucormycosis: Case report.

21. Magnetic resonance imaging-based radiomics nomogram for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer.

22. Environmental explanation of prostate cancer progression based on the comprehensive analysis of polychlorinated biphenyls.

23. Kaempferol efficacy in metabolic diseases: Molecular mechanisms of action in diabetes mellitus, obesity, non-alcoholic fatty liver disease, steatohepatitis, and atherosclerosis.

24. Ubiquitin-specific protease 5 promotes bladder cancer progression through stabilizing Twist1.

25. Identification macrophage signatures in prostate cancer by single-cell sequencing and machine learning.

26. Neonatal stress disrupts the glymphatic system development and increases the susceptibility to Parkinson's disease in later life.

27. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.

28. A computed tomography-based comprehensive standardized adrenal tumor scoring model for predicting the perioperative outcomes of retroperitoneal laparoscopic adrenal surgery.

29. Fatty acid metabolism-related molecular subtypes and a novel model for predicting prognosis in bladder cancer patients.

31. Exploring Novel Genome Instability-associated lncRNAs and their Potential Function in Pan-Renal Cell Carcinoma.

32. Revealing the potential of solute carrier family 31 (copper transporters), member 1: Insights into its role in bladder cancer progression and therapeutic implications.

33. ND630 controls ACACA and lipid reprogramming in prostate cancer by regulating the expression of circKIF18B_003.

34. LncRNA H19-EZH2 interaction promotes liver fibrosis via reprogramming H3K27me3 profiles.

35. The effect of body mass index on quality of life in modified single stoma cutaneous ureterostomy or ileal conduit after radical cystectomy.

36. Head-to-head comparisons of enhanced CT, 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in identifying adverse pathology of clear-cell renal cell carcinoma: a prospective study.

37. Characteristics and prognostic implications of peripheral blood lymphocyte subsets in patients with anti-MDA5 antibody positive dermatomyositis-interstitial lung disease.

38. A tumor-associated macrophages related model for predicting biochemical recurrence and tumor immune environment in prostate cancer.

39. A novel CD8 + T cell-related gene signature for predicting the prognosis and immunotherapy efficacy in bladder cancer.

40. Semantic Computed Tomography Features for Predicting BRCA1-associated Protein 1 and/or Tumor Protein p53 Gene Mutation Status in Clear Cell Renal Cell Carcinoma.

41. Low TLR and PSMA-TV predict biochemical response to abiraterone acetate in metastatic prostate cancer patients developing castration resistance after chemohormonal therapy at hormone-sensitive stage.

42. Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer.

43. Exosomal MiR-381 from M2-polarized macrophages attenuates urethral fibroblasts activation through YAP/GLS1-regulated glutaminolysis.

44. Subtype and prognostic analysis of immunogenic cell death-related gene signature in prostate cancer.

45. Integrative Analysis Developing and Validating Potential Candidate Biomarkers for Cancer Stemness Features of Pan-Renal Cell Carcinoma.

46. CEBPD is a master transcriptional factor for hypoxia regulated proteins in glioblastoma and augments hypoxia induced invasion through extracellular matrix-integrin mediated EGFR/PI3K pathway.

47. Risk factors for lymphorrhea and lymphocele after radical prostatectomy: a retrospective case-control study.

48. Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration-resistant prostate cancer.

49. A Liquid-Liquid Phase Separation-Related Index Associate with Biochemical Recurrence and Tumor Immune Environment of Prostate Cancer Patients.

50. Head-to-head comparisons of [ 68 Ga]Ga-PSMA-11 PET/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study.

Catalog

Books, media, physical & digital resources